allotment, page-46

6ULDV8- I suggest you start trolling through the threads, you've got lots of reading to do.....

In basic terms, the recent Ph2a HCV trail of BIT225 showed a significant improvement from SOC( standard of care)- 87% to 67%. However since the sample group was small (24 patients), then the difference could become statistically insignificant....There could be further data to follow that changes this though- also remember we have HIV trail results to follow(Remember BIT225 is a dual treatment HCV/HIV- around 30-40% of the HIV-infected population in the United State are co-infected). Like RGC68 stated- further "partnered" trails with bigger sample groups will most likely be required... and will most likely happen.....

RGC68 takes things from a clinical perspective and usually offers great insight. However from an investors perspective, BIT is certainly undervalued..... Hep C is the most contested market place in the world at the moment- HIV is another story in itself( All the big boys are battling it out), we've very fortunate to have found ourselves in this position.